Drug Trial Radar · NCT01006265
Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Mar 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
464
Actual
Start
Oct 1, 2009
Primary completion
Jun 1, 2011
Study completion Jul 1, 2011
Sponsor
- Lead sponsor
- ActelionJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Nov 2, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the efficacy, safety, and tolerability of ACT-128800 in patients with relapsing-remitting multiple sclerosis.
Conditions
- Multiple Sclerosis
Interventions
ACT-128800 Dose 1Drug
ACT-128800 (Dose 1) administered orally once daily
PlaceboDrug
Matching placebo administered orally once daily
ACT-128800 Dose 2Drug
ACT-128800 (Dose 2) administered orally once daily
ACT-128800 Dose 3Drug
ACT-128800 (Dose 3) administered orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cumulative Number of New T1 Gadolinium-Enhancing (Gd+) Lesions on Magnetic Resonance Imaging (MRI) Scan From Week 12 to Week 24Time frame: From Week 12 to 24
Locations
115 sites in 23 countries. Site status is shown where the registry gives one.
Clinical Investigative Site 3132
Scottsdale, Arizona
Clinical Investigative Site 3100
Tucson, Arizona
Clinical Investigative Site 3115
Sacramento, California
Clinical Investigative Site 3117
Stanford, California
Clinical Invesigative Site 3116
Sarasota, Florida
Clinical Investigative Site 3101
Indianapolis, Indiana
Clinical Investigative Site 3105
Kansas City, Kansas
Clinical Investigative Site 3107
Lenexa, Kansas
Clinical Investigative Site 3118
Baltimore, Maryland
Clinical Investigative Site 3133
Worcester, Massachusetts
Clinical Investigator 3136
St Louis, Missouri
Clinical Investigative Site # 3135
Newark, New Jersey
Clinical Investigative Site 3129
Latham, New York
Clinical Investigative Site # 3128
New York, New York
Clinical Investigative Site 3127
Schenectady, New York
Clinical Investigative Site 3120
Stony Brook, New York
Clinical Investigative Site 3119
Raleigh, North Carolina
Clinical Investigator 3126
Akron, Ohio
Clinical Investigative Site 3113
Cincinnati, Ohio
Clinical Investigative Site 3130
Columbus, Ohio
Clinical Investigator 3104
Portland, Oregon
Clinical Investigative Site 3125
Philadelphia, Pennsylvania
Clinical Investigative Site 3112
Burlington, Vermont
Clinical Investigative Site 3111
Richmond, Virginia
Clinical Investigative Site 3102
Kirkland, Washington
Clinical Investigative Site # 1001
Fitzroy, Australia
Clinical Investigative Site 1000
Westmead, Australia
Clinical Investigative Site 1102
Amstetten, Austria
Clinical Investigative Site 1100
Sankt Pölten, Austria
Clinical Investigative Site 1101
Vienna, Austria
Clinical Investigative Site 1201
La Louvière, Belgium
Clinical Investigative Site # 1205
Liège, Belgium
Clinical Investigative Site 1204
Ottignies, Belgium
Clinical Investigative Site 1203
Sijsele-Damme, Belgium
Clinical Investigative Site 1302
Sofia, Bulgaria
Clinical Investigative Site 1301
Sofia, Bulgaria
Clinical Investigative Site 1303
Varna, Bulgaria
Clinical Investigative Site 1304
Varna, Bulgaria
Clinical Investigative Site # 1401
Burnaby, Canada
Clinical Investigative Site 1400
Ottawa, Canada
Showing 40 of 115 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.